Login
Home
Charts
Search
Watchlist
Products

Niva Bupa Health Insurance Company Ltd

NIVABUPA·NSE
80.23-0.74%Wed, 23 Sept '26 15:31

Niva Bupa Health Insurance Company Ltd

NIVABUPA
NSE
80.23
-0.74%
|Wed, 23 Sept '26 15:31
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
14,794Cr
Close
Close Price
80.00
Industry
Industry
Finance - Insurance
PE
Price To Earnings
84.21
PS
Price To Sales
1.98
Revenue
Revenue
7,478Cr
Rev Gr TTM
Revenue Growth TTM
26.02%
PAT Gr TTM
PAT Growth TTM
-42.64%

Quarterly Results

Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
9921,0331,3191,1591,3601,2411,5651,7691,5381,5502,1162,274
Growth YoY
Revenue Growth YoY%
33.830.036.137.120.118.652.613.124.935.228.6
Expenses
ExpensesCr
9691,0211,1521,1361,3011,2371,4701,7611,6001,6852,0052,173
Operating Profit
Operating ProfitCr
231216723583958-62-136111101
OPM
OPM%
2.31.112.62.04.30.36.10.4-4.0-8.85.34.4
Other Income
Other IncomeCr
189230304277320315357587334386725661
Interest Expense
Interest ExpenseCr
000000000000
PBT
PBTCr
-85157-19131320698-35-88181184
Tax
TaxCr
000000026002146
PAT
PATCr
-85157-19131320671-35-88159138
Growth YoY
PAT Growth YoY%
-403.6302.273.9271.5189.131.2479.6-370.9-761.9-22.792.9
NPM
NPM%
-0.80.411.9-1.61.01.113.24.0-2.3-5.77.56.1
EPS
EPS
0.00.00.00.00.00.11.10.4-0.2-0.50.90.8
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
9921,0331,3191,1591,3601,2411,5651,7691,5381,5502,1162,274
Growth YoY
Revenue Growth YoY%
33.830.036.137.120.118.652.613.124.935.228.6
Expenses
ExpensesCr
9691,0211,1521,1361,3011,2371,4701,7611,6001,6852,0052,173
Operating Profit
Operating ProfitCr
231216723583958-62-136111101
OPM
OPM%
2.31.112.62.04.30.36.10.4-4.0-8.85.34.4
Other Income
Other IncomeCr
189230304277320315357587334386725661
Interest Expense
Interest ExpenseCr
000000000000
PBT
PBTCr
-85157-19131320698-35-88181184
Tax
TaxCr
000000026002146
PAT
PATCr
-85157-19131320671-35-88159138
Growth YoY
PAT Growth YoY%
-403.6302.273.9271.5189.131.2479.6-370.9-761.9-22.792.9
NPM
NPM%
-0.80.411.9-1.61.01.113.24.0-2.3-5.77.56.1
EPS
EPS
0.00.00.00.00.00.11.10.4-0.2-0.50.90.8

Profit & Loss

Standalone
Numbers
Percentage
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
2,1123,1614,1965,3246,4747,478
Growth
Revenue Growth%
49.732.726.921.626.0
Expenses
ExpensesCr
2,9233,9915,0156,2277,7087,463
Operating Profit
Operating ProfitCr
-811-829-819-903-1,23515
OPM
OPM%
-38.4-26.2-19.5-17.0-19.10.2
Other Income
Other IncomeCr
036421814212,105
Interest Expense
Interest ExpenseCr
000000
PBT
PBTCr
-1971382214127242
Tax
TaxCr
0000-467
PAT
PATCr
-1971382214131174
Growth
PAT Growth%
106.4552.7160.9-38.8-42.6
NPM
NPM%
-9.30.41.94.02.02.3
EPS
EPS
-1.40.10.51.22.00.9
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
2,1123,1614,1965,3246,4747,478
Growth
Revenue Growth%
49.732.726.921.626.0
Expenses
ExpensesCr
2,9233,9915,0156,2277,7087,463
Operating Profit
Operating ProfitCr
-811-829-819-903-1,23515
OPM
OPM%
-38.4-26.2-19.5-17.0-19.10.2
Other Income
Other IncomeCr
036421814212,105
Interest Expense
Interest ExpenseCr
000000
PBT
PBTCr
-1971382214127242
Tax
TaxCr
0000-467
PAT
PATCr
-1971382214131174
Growth
PAT Growth%
106.4552.7160.9-38.8-42.6
NPM
NPM%
-9.30.41.94.02.02.3
EPS
EPS
-1.40.10.51.22.00.9

Balance Sheet

Standalone
Numbers
Percentage
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026Jun 2026
Equity Capital
Equity CapitalCr
1,4091,5111,7001,8271,8470
Reserves
ReservesCr
-903-6831,2831,9491,9390
Borrowings
BorrowingsCr
2502502502502500
Other Liabilities
Other LiabilitiesCr
00-932-718-5840
Total Liabilities
Total LiabilitiesCr
7561,0782,3013,3083,4520
Fixed Assets
Fixed AssetsCr
5975880
Advances
AdvancesCr
2293535321,2891,325
Cash Equivalents
Cash EquivalentsCr
591021432201590
Other Assets
Other AssetsCr
4686231,5671,7231,8800
Total Assets
Total AssetsCr
7561,0782,3013,3083,4520
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026Jun 2026
Equity Capital
Equity CapitalCr
1,4091,5111,7001,8271,8470
Reserves
ReservesCr
-903-6831,2831,9491,9390
Borrowings
BorrowingsCr
2502502502502500
Other Liabilities
Other LiabilitiesCr
00-932-718-5840
Total Liabilities
Total LiabilitiesCr
7561,0782,3013,3083,4520
Fixed Assets
Fixed AssetsCr
5975880
Advances
AdvancesCr
2293535321,2891,325
Cash Equivalents
Cash EquivalentsCr
591021432201590
Other Assets
Other AssetsCr
4686231,5671,7231,8800
Total Assets
Total AssetsCr
7561,0782,3013,3083,4520

Cash Flow

Standalone
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
3385938131,654905
Investing Cash Flow
Investing Cash FlowCr
-723-829-1,882-2,348-961
Financing Cash Flow
Financing Cash FlowCr
3742801,110771-5
Net Cash Flow
Net Cash FlowCr
-12434178-62
Free Cash Flow
Free Cash FlowCr
3095557801,614857
CFO To PAT
CFO To PAT%
-171.94,724.6992.9774.8691.9
CFO To EBITDA
CFO To EBITDA%
-41.6-71.5-99.2-183.2-73.3
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
3385938131,654905
Investing Cash Flow
Investing Cash FlowCr
-723-829-1,882-2,348-961
Financing Cash Flow
Financing Cash FlowCr
3742801,110771-5
Net Cash Flow
Net Cash FlowCr
-12434178-62
Free Cash Flow
Free Cash FlowCr
3095557801,614857
CFO To PAT
CFO To PAT%
-171.94,724.6992.9774.8691.9
CFO To EBITDA
CFO To EBITDA%
-41.6-71.5-99.2-183.2-73.3

Ratios

Standalone
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
14,25312,95414,794
Price To Earnings
Price To Earnings
66.798.884.2
Price To Sales
Price To Sales
2.61.92.0
Price To Book
Price To Book
3.83.43.9
EV To EBITDA
EV To EBITDA
-15.8-10.61,023.5
Profitability Ratios
Profitability Ratios
OPM
OPM%
-38.4-26.2-19.5-17.0-19.10.2
NPM
NPM%
-9.30.41.94.02.02.3
ROCE
ROCE%
-26.01.22.55.33.1
ROE
ROE%
-38.91.52.75.73.5
ROA
ROA%
-26.01.23.66.53.8
Solvency Ratios
Solvency Ratios
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
14,25312,95414,794
Price To Earnings
Price To Earnings
66.798.884.2
Price To Sales
Price To Sales
2.61.92.0
Price To Book
Price To Book
3.83.43.9
EV To EBITDA
EV To EBITDA
-15.8-10.61,023.5
Profitability Ratios
Profitability Ratios
OPM
OPM%
-38.4-26.2-19.5-17.0-19.10.2
NPM
NPM%
-9.30.41.94.02.02.3
ROCE
ROCE%
-26.01.22.55.33.1
ROE
ROE%
-38.91.52.75.73.5
ROA
ROA%
-26.01.23.66.53.8
Solvency Ratios
Solvency Ratios
- **Niva Bupa is a pure-play health insurer that protects over 25 million Indians from medical expenses, built on a joint venture between India’s Max Group and the UK’s Bupa - a global healthcare organisation founded in 1947 that reinvests its profits rather than paying shareholders. The company, which rebranded from Max Bupa to Niva Bupa in July 2021 and listed on Indian stock exchanges in late 2024, has grown to become the third-largest retail health insurer among India’s standalone health insurers, with a 10.1% market share. Its recurring approach is to use Bupa’s global expertise in actuarial science, digital health and customer experience as a foundation, then localise everything - products, distribution, claims networks and a wellness app - for Indian incomes, Indian cities and Indian healthcare realities.** # Business segments Two engines that feed each other - a retail health book that is the strategic core and a disciplined group health business that provides scale - supported by a small personal-accident and travel line. ## 1. Retail health insurance: the strategic core **A portfolio of indemnity and fixed-benefit health plans designed to cover every paying Indian from millennials to seniors, sold through a multi-channel network that reaches every pin code.** - **Flagship product with category-first features** - ReAssure, the company’s core offering, comes in multiple variants (GoActive, 2.0, 3.0) and includes benefits the company describes as industry firsts, anchoring a suite that spans wellness-focused plans, disease-management covers and tiered-network options. - **Products sliced by life stage and wallet** - the range runs from Rise (a mass-market plan for Tier 3 and 4 cities with monthly “Flexi Pay” instalments and return benefits at maturity) through ReAssure for the affluent, Health Premia for high-net-worth individuals, Aspire and Elixir for millennials and Gen Z, and Senior First for older customers, covering “practically every income segment, except poor or near poor people”. - **Bancassurance and agents do the heavy lifting** - individual agents bring in 30.2% of group-wide premium and corporate-agent banks another 29.5%, with HDFC Bank, Axis Bank and Bank of Baroda among the largest bancassurance partnerships in the standalone-health-insurer space. - **A Bharat strategy for the next wave** - the company targets Tier 3 cities and below through bank distribution and a virtual agency model, giving it access to every pin code in India while adding roughly 58,000 individual agents in a single year. - **Renewals are half the engine** - premium income on the retail side splits roughly 40:60 between fresh and renewal business, so the book compounds as customers stay, and the average ticket size has reached about ₹31,000 per policy. ## 2. Group health insurance: the scale companion **Corporate health covers sold to businesses, run with tight pricing discipline and a deliberate tilt toward small and medium enterprises to keep the portfolio balanced.** - **A B2B book that funds the platform** - group business contributes 31.6% of gross written premium, providing a large, relatively stable pool of lives that complements the retail engine. - **SME focus keeps risk in check** - the company actively manages the mix toward small and medium enterprises rather than chasing a few large corporate accounts, which helps avoid the pricing swings that come with big-ticket group tenders. - **Most risk is retained** - the company keeps 79.3% of the premium it writes on its own balance sheet across both retail and group books, meaning it underwrites rather than simply passing risk to reinsurers. ## 3. Personal accident and travel insurance: the add-on line **A small suite of personal-accident and international-travel plans that rounds out the product shelf for individuals and corporates.** - **A 1.4% contributor that completes the offering** - these policies exist so that existing retail and group customers can buy related covers from the same insurer, but they are not a standalone growth engine. # Digital health and wellness ecosystem **A mobile app with 14 million downloads that turns insurance from a once-a-year claims relationship into a daily health companion - and rewards customers who stay healthy with premium discounts.** - **Built on Bupa’s Blua platform, localised for India** - the app offers medicine delivery, at-home diagnostic sample collection, digital doctor consultations, second medical opinions, ambulance booking and a hospital-discovery tool that lets customers check hospitalisation expenses before admission. - **Wellness discounts change behaviour** - customers who record 10,000 steps daily on the app can earn up to a 30% discount on renewal premiums, and a separate favourable-claims-experience discount is also available, so healthier customers pay less. - **Chronic-condition management keeps high-risk lives engaged** - the platform runs programmes for ongoing conditions, which helps the company stay close to customers whose health costs might otherwise surprise the claims book. # Group structure and partners **A single legal entity with no subsidiaries, backed by a global healthcare parent that provides the technical and digital backbone - and a small stake in India’s emerging insurance marketplace.** - **Bupa is the controlling shareholder and knowledge partner** - Bupa Singapore Holdings holds 55.36% and, together with Bupa Investments Overseas, acts as promoter, giving Niva Bupa access to actuarial insights, a structured Net Promoter Score programme across more than 25 customer touchpoints, and the Blua digital health platform that underpins its app. - **No subsidiaries, no joint ventures** - the company operates as a single corporate entity, so all its insurance, investment and distribution activities sit on one balance sheet. - **A 1.51% stake in Bima Sugam** - in early 2025, Niva Bupa invested ₹5 crore in the equity of Bima Sugam India Federation, a not-for-profit digital insurance marketplace being built under IRDAI regulations to connect customers, insurers and intermediaries on a single platform.

Documents — Niva Bupa Health Insurance Company Ltd

  • Q1 FY2027 Earnings Call Transcript (Jun 2026, PDF): https://www.stockscans.in/document/ekk4nydqa108nsqu8e6c6z3i.pdf
  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/in0kgnorpsx6s5o9zhzimbds.pdf
  • Q3 FY2026 Earnings Call Transcript (Dec 2025, PDF): https://www.stockscans.in/document/fxs4nylij3gvlstk2q618pqn.pdf
  • Q2 FY2026 Earnings Call Transcript (Sep 2025, PDF): https://www.stockscans.in/document/wgzwuqjushf1q6x6n6wr7f5y.pdf
  • Q1 FY2026 Earnings Call Transcript (Jun 2025, PDF): https://www.stockscans.in/document/7wzyif3802t2qonn7hbs7thn.pdf
  • Q4 FY2025 Earnings Call Transcript (Mar 2025, PDF): https://www.stockscans.in/document/h9u01iys7tbmj798ueczw62s.pdf
  • Q3 FY2025 Earnings Call Transcript (Dec 2024, PDF): https://www.stockscans.in/document/35su76i7u2ul1agurm4buwco.pdf
  • Q2 FY2025 Earnings Call Transcript (Sep 2024, PDF): https://www.stockscans.in/document/3ja0tqivjp80jmfgqfxm281c.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/xc745201bvljqjsl9sowlnai.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/uzf6y3kh1gl6ymq427zd3xki.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/qfulkijy4wtyzxo2d3br78jf.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/zlj6ihl9zxv86102nnvox4gj.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/s54oi6y35zwmf8kdmsspqcyu.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/py5ajfa0mz43lq75jzthx8jh.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/s9brm446k2okry9n9980jyrg.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/xbpoqox19n4wrt8p331b0fc9.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/ysjfguyfvqzq62mq2gf63h6l.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/g0onff9jto2gmka12yd8imtn.pdf
  • Q3 FY2026 Investor Presentation (Dec 2025, PDF): https://www.stockscans.in/document/ca5bm57oq0q5rziiq8sl22pw.pdf
  • Q2 FY2026 Investor Presentation (Sep 2025, PDF): https://www.stockscans.in/document/kyiim7c5egy91880tv6kn0sv.pdf
  • Q1 FY2026 Investor Presentation (Jun 2025, PDF): https://www.stockscans.in/document/ogqt3u0dxdritvdg8p9gkr2b.pdf
  • Q4 FY2025 Investor Presentation (Mar 2025, PDF): https://www.stockscans.in/document/2co4bhfxk9f3fzfwerwifpyf.pdf
  • Q3 FY2025 Investor Presentation (Dec 2024, PDF): https://www.stockscans.in/document/7tb69w6tylfkkag9k0m9gk7a.pdf
  • Q2 FY2025 Investor Presentation (Sep 2024, PDF): https://www.stockscans.in/document/gzteiv2c5ngl1xk0o0oeakpz.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/jjcl5j14y3xetwk8kspds1zg.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/tlx4chu8h7yn4goc3h03gm1a.pdf

Concall Transcript Summaries — Niva Bupa Health Insurance Company Ltd

  • Q1 FY2027 Concall Transcript Summary (Jun 2026): https://www.stockscans.in/company/NSE%3ANIVABUPA/transcript-notes/202606/ekk4nydqa108nsqu8e6c6z3i.pdf
  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/NSE%3ANIVABUPA/transcript-notes/202603/in0kgnorpsx6s5o9zhzimbds.pdf
  • Q3 FY2026 Concall Transcript Summary (Dec 2025): https://www.stockscans.in/company/NSE%3ANIVABUPA/transcript-notes/202512/fxs4nylij3gvlstk2q618pqn.pdf
  • Q2 FY2026 Concall Transcript Summary (Sep 2025): https://www.stockscans.in/company/NSE%3ANIVABUPA/transcript-notes/202509/wgzwuqjushf1q6x6n6wr7f5y.pdf
  • Q1 FY2026 Concall Transcript Summary (Jun 2025): https://www.stockscans.in/company/NSE%3ANIVABUPA/transcript-notes/202506/7wzyif3802t2qonn7hbs7thn.pdf
  • Q4 FY2025 Concall Transcript Summary (Mar 2025): https://www.stockscans.in/company/NSE%3ANIVABUPA/transcript-notes/202503/h9u01iys7tbmj798ueczw62s.pdf
  • Q3 FY2025 Concall Transcript Summary (Dec 2024): https://www.stockscans.in/company/NSE%3ANIVABUPA/transcript-notes/202412/35su76i7u2ul1agurm4buwco.pdf
  • Q2 FY2025 Concall Transcript Summary (Sep 2024): https://www.stockscans.in/company/NSE%3ANIVABUPA/transcript-notes/202409/3ja0tqivjp80jmfgqfxm281c.pdf